In vitro and in vivo resistance to human immunodeficiency virus type 1 entry inhibitors

Medicine and Dentistry

• Fusion Inhibitor 100%
• Human Immunodeficiency Virus 1 50%
• In Vitro 33%
• Antivirus Agent 33%
• Virus Entry 33%
• Receptor 16%
• Enfuvirtide 16%
• Human Immunodeficiency Virus Fusion Inhibitor 16%
• Maraviroc 16%
• Therapeutic Procedure 16%
• Patient 16%
• Comprehension 16%

Immunology and Microbiology

• Human Immunodeficiency Virus 1 50%
• CCR5 33%
• Viral Entry 33%
• CD4 16%
• Cell Membrane 16%
• CXCR4 16%
• Gp41 16%
• Comprehension 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Human Immunodeficiency Virus 1 50%
• Antivirus Agent 33%
• Receptor 16%
• Human Immunodeficiency Virus Fusion Inhibitor 16%
• Enfuvirtide 16%
• Maraviroc 16%